EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vanda Pharmaceuticals's Enterprise Value is $165.6 Mil.
Vanda Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-137.3 Mil. Therefore, Vanda Pharmaceuticals's EV-to-FCF for today is -1.21.
The historical rank and industry rank for Vanda Pharmaceuticals's EV-to-FCF or its related term are showing as below:
LTS:0LKB'
s EV-to-FCF Range Over the Past 10 Years
Min: -205.86 Med: 2.48 Max: 315.65
Current: -1.21
During the past 13 years, the highest EV-to-FCF of Vanda Pharmaceuticals was 315.65. The lowest was -205.86. And the median was 2.48.
LTS:0LKB's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 14.97
vs LTS:0LKB: -1.21
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vanda Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Vanda Pharmaceuticals's share price for today is $5.91.
Vanda Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LKB vs FBRX, ARTV, OABI: EV-to-FCF Comparison
For the Biotechnology subindustry, Vanda Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's EV-to-FCF falls into.
Vanda Pharmaceuticals's current Enterprise Value is $165.6 Mil.
Vanda Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-137.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals (LTS:0LKB) has a EV-to-FCF of -1.21 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vanda Pharmaceuticals and its competitors. According to the industry distribution chart, Vanda Pharmaceuticals ranks #999999 out of 330 companies in the Biotechnology industry.
Is Vanda Pharmaceuticals' EV-to-FCF too high?
Vanda Pharmaceuticals' current EV-to-FCF is -1.21. Based on the distribution chart, Vanda Pharmaceuticals ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vanda Pharmaceuticals has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' EV-to-FCF compare to FBRX and ARTV?
According to the Biotechnology industry distribution chart, Vanda Pharmaceuticals ranks #999999 out of 330 companies for EV-to-FCF. This places Vanda Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 14.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.97, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vanda Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanda Pharmaceuticals's current EV-to-FCF is -1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (LTS:0LKB) is currently considered Fairly Valued. The stock's GF Value™ is $5.48, compared to a current price of $5.91 — trading 7.8% above its estimated fair value. The current EV-to-FCF is -1.21. Vanda Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vanda Pharmaceuticals (LTS:0LKB), the current EV-to-FCF is -1.21 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanda Pharmaceuticals (LTS:0LKB) Overvalued in 2026?
Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued.
The current stock price of $5.91 is trading 7.8% above its estimated GF Value™ of $5.48.
GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0LKB:
EV-to-FCF: -1.21
GF Value™: $5.48 vs. price of $5.91 (7.8% above fair value)
No single metric tells the full story. See the LTS:0LKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
71GF Score
Get the complete analysis for LTS:0LKB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LKB has been successfully added to your 
